SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-084866
Filing Date
2024-10-03
Accepted
2024-10-03 09:39:08
Documents
20
Period of Report
2024-10-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0216649-8k_onconetix.htm   iXBRL 8-K 98345
2 CERTIFICATE OF DESIGNATIONS AUTHORIZING THE ISSUANCE OF THE SERIES C PREFERRED S ea021664901ex3-1_onconetix.htm EX-3.1 316065
3 FORM OF WARRANT ea021664901ex4-1_onconetix.htm EX-4.1 179502
4 FORM OF SECURITIES PURCHASE AGREEMENT DATED OCTOBER 2, 2024 RELATING TO THE SALE ea021664901ex10-1_onconetix.htm EX-10.1 309622
5 FORM OF REGISTRATION RIGHTS AGREEMENT DATED AS OF OCTOBER 2, 2024 RELATING TO TH ea021664901ex10-2_onconetix.htm EX-10.2 176796
6 FORM OF ELOC PURCHASE AGREEMENT DATED OCTOBER 2, 2024 ea021664901ex10-3_onconetix.htm EX-10.3 511250
7 FORM OF ELOC REGISTRATION RIGHTS AGREEMENT DATED OCTOBER 2, 2024 ea021664901ex10-4_onconetix.htm EX-10.4 145654
8 PRESS RELEASE DATED OCTOBER 3, 2024 ea021664901ex99-1_onconetix.htm EX-99.1 11001
  Complete submission text file 0001213900-24-084866.txt   2319731

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE onco-20241002.xsd EX-101.SCH 3042
10 XBRL LABEL FILE onco-20241002_lab.xml EX-101.LAB 34240
11 XBRL PRESENTATION FILE onco-20241002_pre.xml EX-101.PRE 22377
22 EXTRACTED XBRL INSTANCE DOCUMENT ea0216649-8k_onconetix_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 241350100
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)